Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide 50 mg in Chinese adults with overweight or obesity
NCT05890976Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2023
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started May 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05890976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890976.